Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | OGA | O60502 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 8/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14217158 | 0.98 | UBE2T (0.45) | UBE2TMAPTOGAALDH1A1LMNA | |
| SCHEMBL14217201 | 0.98 | UBE2T (0.45) | UBE2TMAPTOGAALDH1A1LMNA | |
| SCHEMBL11989555 | 0.89 | HRH4 (0.41) | OGAALDH1A1SMN1; SMN2 | |
| SCHEMBL14217156 | 0.88 | ALDH1A1 (0.44) | OGAALDH1A1SMN1; SMN2 | |
| SCHEMBL11989613 | 0.88 | ALDH1A1 (0.44) | OGAALDH1A1SMN1; SMN2 | |
| SCHEMBL11989546 | 0.88 | ALDH1A1 (0.44) | OGAALDH1A1SMN1; SMN2 | |
| SCHEMBL11989577 | 0.86 | OGA (0.48) | OGA | |
| SCHEMBL14217157 | 0.85 | MAPT (0.50) | MAPTOGAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14217162 | 0.84 | KDM4E (0.48) | OGA | |
| SCHEMBL11989549 | 0.84 | KDM4E (0.48) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247421-B2 | 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100189773-A1 | 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189773-A1 | 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K5, CDK5, MAP3K20 | UBE2T 4377/4885MAPT 1661/4885OGA 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.